EZH2 and neoplasm: Whereas KRAS tumour organoids were significantly decreased when passaged in continued 5 μM GSK126, organoids grown in the presence of tamoxifen (and therefore Lkb1 null) were equally passaged in continued presence of the EZH2 inhibitor (P=0.0113 for Kras, P=0.132 for KRAS/Lkb1; Supplementary Fig. 4d).